ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

AVAPRO
Diabetes
Hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

AVAPRO Rx

Generic Name and Formulations:
Irbesartan 75mg, 150mg, 300mg; tabs.

Company:
Sanofi Aventis

Therapeutic Use:

Indications for AVAPRO:

Treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension.

Adult:

300mg once daily.

Children:

Not recommended.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy, or reduce initial dose. Renal impairment. Severe CHF. Renal artery stenosis. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Interactions:

Hyperkalemia with K+ supplements, K+ sparing diuretics, K+-containing salt substitutes. May increase lithium levels; monitor. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Diarrhea, dyspepsia, fatigue, orthostatic hypotension; increased BUN, hyperkalemia; rhabdomyolysis (rare).

Metabolism:

Hepatic (CYP2C9); 90% protein bound.

Elimination:

Biliary, renal.

Generic Availability:

YES

How Supplied:

Tabs—30, 90

Indications for AVAPRO:

Hypertension.

Adult:

≥16yrs: 150mg once daily; may increase to 300mg once daily. Or, may add a low dose of diuretic. Salt/volume depletion: initially 75mg once daily.

Children:

Not recommended.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy, or reduce initial dose. Renal impairment. Severe CHF. Renal artery stenosis. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Interactions:

Hyperkalemia with K+ supplements, K+ sparing diuretics, K+-containing salt substitutes. May increase lithium levels; monitor. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Diarrhea, dyspepsia, fatigue; increased BUN, hyperkalemia; rhabdomyolysis (rare).

Metabolism:

Hepatic (CYP2C9); 90% protein bound.

Elimination:

Biliary, renal.

Generic Availability:

YES

How Supplied:

Tabs—30, 90

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs